Enanta Pharmaceuticals | ENTA - Дебиторская задолженность





Дебиторская задолженность Изменить Дата
AbbVie USD 12.59B 180M 2025-12
Amgen USD 9.14B 432M 2026-03
Anika Therapeutics USD 29.33M 661K 2025-12
Arrowhead Research USD 15.68M 203.19M 2026-03
AstraZeneca USD 17.88B 1.17B 2026-03
BioCryst Pharmaceuticals USD 106.82M 15.49M 2025-12
Biogen USD 1.79B 76.6M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Gilead Sciences USD 4.74B 172M 2026-03
GlaxoSmithKline GBP 7.94B 178M 2026-03
Halozyme Therapeutics USD 457.99M 16.72M 2026-03
Heron Therapeutics USD 89.59M 8.54M 2025-12
Immunic USD 333K 156K 2025-12
Incyte USD 1.05B 27.09M 2026-03
Insmed USD 178.55M 37.7M 2026-03
Ionis Pharmaceuticals USD 74M 8M 2026-03
J&J USD 21.33B 3.72B 2025-12
Karyopharm Therapeutics USD 26.18M 5.6M 2025-12
Ligand Pharmaceuticals USD 54.8M 6.25M 2026-03
Merck USD 11.78B 345M 2025-12
Neurocrine Biosciences USD 768.1M 81.3M 2026-03
Novartis USD 9.6B 2.69B 2026-03
Novavax USD 106.45M 72.27M 2025-12
Pfizer USD 16.17B 332M 2026-03
PTC Therapeutics USD 181.62M 21.45M 2025-12
Roche Holding CHF 11.9B 460M 2025-12
Sarepta Therapeutics USD 547.91M 149.68M 2026-03
Vertex Pharmaceuticals USD 2B 56.7M 2026-03